CurifyLabs, a Finnish health technology company developing automated compounding systems for personalised medicines, has raised €12M in a Series A round co-led by Sandwater and HealthCap, with participation from Tesi, existing investor Lifeline Ventures, and a number of US-based customers and employees.
Founded in 2021 by Charlotta Topelius and Niklas Sandler, the company will use the funding to expand its operations in the United States, strengthen its supply chain, and accelerate development of new products including its latest compounding system, the PharmaPrinter Aurum.
Addressing The Market Opportunity
Personalised medicines, prepared by pharmacies to meet the specific needs of individual patients, are typically compounded through manual processes that are time-consuming, variable in consistency, and difficult to scale. As demand for personalised treatment grows across healthcare systems, the gap between what manual compounding can reliably deliver and what patients and providers need has become increasingly apparent.
CurifyLabs was built to address this gap by automating the compounding process in a way that improves accuracy, consistency, and safety without requiring pharmacies to overhaul their existing operations entirely.
Advertisement
How The Technology Works
CurifyLabs’ Compounding System combines advanced software, high-quality pharmaceutical ingredients, and 3D printing technology to automate the preparation of personalised medicines at the pharmacy level. The platform is designed to make compounding faster and more consistent than traditional manual methods, with built-in quality control features that help ensure every medicine is prepared to the same standard each time.
The system is intended to give pharmacies and healthcare providers the tools to meet individual patient needs at scale, reducing variability and improving the reliability of a process that has historically depended heavily on manual skill and experience.
Growth And Market Traction
Founded in 2021, CurifyLabs has built its platform to a point where US-based customers and employees participated directly in the Series A alongside institutional investors, reflecting commercial traction and confidence in the company’s direction. The round brings together investors with deep expertise in health technology and life sciences, including Sandwater, HealthCap, and Lifeline Ventures, which has backed the company since an earlier stage.
Expansion Plans
The Series A will fund CurifyLabs’ expansion into the United States, where the company sees significant demand for automated compounding solutions. The funding will also be used to strengthen the supply chain supporting US operations, improve customer support infrastructure, and accelerate development of new products and technologies, including the PharmaPrinter Aurum.
Looking Ahead
Charlotta Topelius, founder and CEO of CurifyLabs, described the standard the company has held itself to and how the new funding will allow it to build further on that foundation: “This investment reflects the conviction our partners have in what we’re building. We have set a high bar for clinical rigour, product quality and customer support, and this funding gives us the resources to raise that bar further.”
About CurifyLabs
CurifyLabs is a Finnish health technology company founded in 2021 by Charlotta Topelius and Niklas Sandler. The company develops automated compounding systems that help pharmacies prepare personalised medicines with greater speed, accuracy, and consistency than traditional manual methods. Its platform combines advanced software, pharmaceutical ingredients, and 3D printing technology, with built-in quality control at every stage of the process. CurifyLabs is expanding its operations into the United States following its €12M Series A.
